BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Raised to $113.00 at UBS Group

BioMarin Pharmaceutical (NASDAQ:BMRN) had its target price lifted by UBS Group from $109.00 to $113.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. UBS Group’s price objective suggests a potential upside of 66.26% from the stock’s current price.

Several other equities research analysts also recently weighed in on BMRN. Citigroup decreased their price target on BioMarin Pharmaceutical from $93.00 to $81.00 and set a “neutral” rating for the company in a report on Wednesday, October 30th. Robert W. Baird reduced their target price on shares of BioMarin Pharmaceutical from $72.00 to $65.00 and set a “neutral” rating for the company in a research note on Wednesday, October 30th. Evercore ISI dropped their price target on shares of BioMarin Pharmaceutical from $115.00 to $105.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 30th. Cantor Fitzgerald restated an “overweight” rating and issued a $90.00 price objective on shares of BioMarin Pharmaceutical in a research report on Thursday, December 12th. Finally, Wedbush upgraded BioMarin Pharmaceutical to a “strong-buy” rating in a research report on Monday, November 4th. Seven equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $94.15.

BioMarin Pharmaceutical Trading Up 3.6 %

Shares of BioMarin Pharmaceutical stock opened at $67.97 on Thursday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.62 and a current ratio of 4.27. The company has a market capitalization of $12.95 billion, a P/E ratio of 40.67, a PEG ratio of 0.57 and a beta of 0.28. BioMarin Pharmaceutical has a 1 year low of $60.63 and a 1 year high of $94.85. The company’s fifty day moving average is $64.79 and its two-hundred day moving average is $71.06.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.54 by $0.18. The firm had revenue of $747.31 million for the quarter, compared to analyst estimates of $711.05 million. BioMarin Pharmaceutical had a return on equity of 8.53% and a net margin of 11.71%. Analysts forecast that BioMarin Pharmaceutical will post 2.5 earnings per share for the current year.

Institutional Investors Weigh In On BioMarin Pharmaceutical

A number of large investors have recently bought and sold shares of the stock. Creative Planning raised its holdings in shares of BioMarin Pharmaceutical by 20.9% in the third quarter. Creative Planning now owns 14,300 shares of the biotechnology company’s stock worth $1,005,000 after acquiring an additional 2,475 shares during the last quarter. Blue Trust Inc. raised its stake in BioMarin Pharmaceutical by 504.9% in the 3rd quarter. Blue Trust Inc. now owns 859 shares of the biotechnology company’s stock valued at $60,000 after purchasing an additional 717 shares during the last quarter. Sequoia Financial Advisors LLC purchased a new position in BioMarin Pharmaceutical in the 3rd quarter valued at about $279,000. Lecap Asset Management Ltd. acquired a new stake in shares of BioMarin Pharmaceutical during the 3rd quarter worth about $1,009,000. Finally, International Assets Investment Management LLC acquired a new stake in shares of BioMarin Pharmaceutical during the 3rd quarter worth about $12,940,000. Institutional investors and hedge funds own 98.71% of the company’s stock.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.